Safety and Tolerability of Combinations of Empagliflozin/Linagliptin (EMPA/LINA) for 52 Weeks in Subjects with Type 2 Diabetes (T2DM)

被引：0
|
作者：
Patel, Sanjay
Defronzo, Ralph A.
Lewin, Andrew
Liu, Dacheng
Kaste, Renee
Kohler, Sven
Woerle, Hans J.
Broedl, Uli C.
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1259-P
引用
收藏
页码：A326 / A327
页数：2
相关论文
共 50 条
  • [1] Safety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in subjects with type 2 diabetes
    Kohler, S.
    Patel, S.
    DeFronzo, R. A.
    Lewin, A.
    Liu, D.
    Kaste, R.
    Woerle, H. -J.
    Broedl, U.
    [J]. DIABETOLOGIA, 2015, 58 : S363 - S363
  • [2] Consistent Weight Changes Irrespective of Baseline HbA1c with the Combination of Empagliflozin/Linagliptin (EMPA/LINA) in Subjects with Type 2 Diabetes (T2DM)
    Barnett, Anthony H.
    Defronzo, Ralph A.
    Lewin, Andrew
    Patel, Sanjay
    Liu, Dacheng
    Kaste, Renee
    Broedl, Uli C.
    Lee, Christopher
    [J]. DIABETES, 2015, 64 : A656 - A656
  • [3] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2015, 64 : A302 - A303
  • [4] Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM)
    Roden, M.
    Merker, L.
    Christiansen, A. V.
    Roux, F.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Lund, S. S.
    Hach, T.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2014, 57 : S325 - S326
  • [5] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [6] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A278 - A278
  • [7] Fixed dose combinations of empagliflozin and linagliptin for 52 weeks in drug-naive subjects with type 2 diabetes
    Lewin, A.
    DeFronzo, R.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    [J]. DIABETOLOGIA, 2014, 57 : S346 - S347
  • [8] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A69 - A69
  • [9] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael W.
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [10] Safety and Tolerability of Linagliptin and Metformin in Combination for Patients with Type 2 Diabetes Mellitus (T2DM)
    Ross, Stuart A.
    Haak, Thomas
    Patel, Sanjay
    Thiemann, Sandra
    Schumacher, Helmut
    Meinicke, Thomas
    [J]. DIABETES, 2014, 63 : A277 - A277
12345